Brian N. Ross
YOU?
Author Swipe
View article: <i>Ex vivo</i> and <i>in vivo</i> HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract
<i>Ex vivo</i> and <i>in vivo</i> HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract Open
New HIV latency-reversing agents (LRAs) are needed that can reactivate and/or eliminate HIV reservoirs. “Mukungulu,” prepared from the plant Croton megalobotrys Müll Arg., is traditionally used for HIV/AIDS management in northern Botswana …
View article: Inferring HIV rebound timing from a noisy biomarker
Inferring HIV rebound timing from a noisy biomarker Open
View article: BCL6 BTB‐specific inhibitor reversely represses T‐cell activation, Tfh cells differentiation, and germinal center reaction in vivo
BCL6 BTB‐specific inhibitor reversely represses T‐cell activation, Tfh cells differentiation, and germinal center reaction in vivo Open
Inhibition of the BCL6 BTB domain results in killing Diffuse Large B‐cell Lymphoma (DLBL) cells, reducing the T‐cell dependent germinal center (GC) reaction in mice, and reversing GC hyperplasia in nonhuman primates. The available BCL6 BTB…
View article: Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption
Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption Open
We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretrovir…
View article: Author response for "BCL6 BTB‐specific inhibitor reversely represses T Cell activation, Tfh cells differentiation and germinal center reaction in vivo"
Author response for "BCL6 BTB‐specific inhibitor reversely represses T Cell activation, Tfh cells differentiation and germinal center reaction in vivo" Open
View article: Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial
Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial Open
In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures in blood and in gut-associated lymphoid tissue (GALT). Twenty …
View article: Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy Open
Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using the intact proviral DNA assay (IPDA), along w…
View article: Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals
Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals Open
Objective: Glycosylation plays a critical role in mediating several antibody (mainly immunoglobulin G; IgG) immunological functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and anti-inflammatory activities. We inves…
View article: NK Response Correlates with HIV Decrease in Pegylated IFN-α2a–Treated Antiretroviral Therapy–Suppressed Subjects
NK Response Correlates with HIV Decrease in Pegylated IFN-α2a–Treated Antiretroviral Therapy–Suppressed Subjects Open
We previously reported that pegylated IFN-α2a (Peg–IFN-α2a) added to antiretroviral therapy (ART)–suppressed, HIV-infected subjects resulted in plasma HIV control and integrated HIV DNA decrease. We now evaluated whether innate NK cell act…
View article: Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women
Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women Open
Identification of factors associated with human papillomavirus (HPV) cervical histopathology or recurrence/relapse following loop electrosurgical excision procedure (LEEP) would allow for better management of the disease. We investigated w…
View article: HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects
HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects Open
Summary The impact of hepatitis C virus ( HCV ) RNA levels on immune status in chronically HCV mono‐infected when compared to HIV / HCV co‐infected on antiretroviral therapy ( ART ) remains poorly understood. A total of 78 African American…
View article: Plasmacytoid dendritic cell and functional <scp>HIV</scp> Gag p55‐specific T cells before treatment interruption can inform set‐point plasma <scp>HIV</scp> viral load after treatment interruption in chronically suppressed <scp>HIV</scp>‐1<sup>+</sup> patients
Plasmacytoid dendritic cell and functional <span>HIV</span> Gag p55‐specific T cells before treatment interruption can inform set‐point plasma <span>HIV</span> viral load after treatment interruption in chronically suppressed <span>HIV</span>‐1<sup>+</sup> patients Open
Summary The identification of immune correlates of HIV control is important for the design of immunotherapies that could support cure or antiretroviral therapy ( ART ) intensification‐related strategies. ART interruptions may facilitate th…